ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Arcus Biosciences Inc

Arcus Biosciences Inc (RCUS)

14.03
-0.09
(-0.64%)
Cerrado 20 Enero 3:00PM
14.03
0.00
(0.00%)
Fuera de horario: 3:25PM

Herramientas de nivel profesional para inversores individuales.

Estadísticas y detalles clave

Último Precio
14.03
Postura de Compra
-
Postura de Venta
-
Volume Operado de la Acción
331,636
13.94 Rango del Día 14.4499
13.51 Rango de 52 semanas 20.31
Capitalización de Mercado [m]
Precio Anterior
14.12
Precio de Apertura
14.39
Última hora de negociación
Volumen financiero
US$ 4,689,353
Precio Promedio Ponderado
14.1401
Volumen promedio (3 m)
698,941
Acciones en circulación
91,511,609
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-4.18
Beneficio por acción (BPA)
-3.35
turnover
117M
Beneficio neto
-307M

Acerca de Arcus Biosciences Inc

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule... Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB680, and Zimberelimab. Arcus conducts clinical trials for different types of cancers such as Prostate, Lung, Colorectal, Pancreatic, and others. The company operates through the single segment being the business of developing and commercializing immunotherapies. Mostrar más

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sitio web
Sede
Camden, Delaware, USA
Fundado
-
Arcus Biosciences Inc is listed in the Pharmaceutical Preparations sector of the New York Stock Exchange with ticker RCUS. The last closing price for Arcus Biosciences was US$14.12. Over the last year, Arcus Biosciences shares have traded in a share price range of US$ 13.51 to US$ 20.31.

Arcus Biosciences currently has 91,511,609 shares in issue. The market capitalisation of Arcus Biosciences is US$1.29 billion. Arcus Biosciences has a price to earnings ratio (PE ratio) of -4.18.

RCUS Últimas noticias

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today...

Arcus Biosciences to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that...

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today...

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today...

Arcus Biosciences to Participate in Two Upcoming Investor Conferences

Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that...

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
1-0.59-4.0355677154614.6214.7213.5159512014.05972291CS
4-1.08-7.147584381215.1116.0813.5160579314.93849841CS
12-4.12-22.699724517918.1518.9813.5169894115.83992266CS
26-1.71-10.864040660715.7418.9813.5166286916.18788135CS
52-2.79-16.587395957216.8220.3113.5171777216.41268095CS
156-20.94-59.879897054634.9739.7512.9586631421.20251932CS
2603.3831.737089201910.6549.18.5575485823.72380566CS

RCUS - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Arcus Biosciences?
El precio actual de las acciones de Arcus Biosciences es US$ 14.03
¿Cuántas acciones de Arcus Biosciences están en circulación?
Arcus Biosciences tiene 91,511,609 acciones en circulación
¿Cuál es la capitalización de mercado de Arcus Biosciences?
La capitalización de mercado de Arcus Biosciences es USD 1.29B
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Arcus Biosciences?
Arcus Biosciences ha negociado en un rango de US$ 13.51 a US$ 20.31 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Arcus Biosciences?
El ratio precio/beneficio de Arcus Biosciences es -4.18
¿Cuál es el ratio de efectivo a ventas de Arcus Biosciences?
El ratio de efectivo a ventas de Arcus Biosciences es 10.97
¿Cuál es la moneda de reporte de Arcus Biosciences?
Arcus Biosciences presenta sus resultados financieros en USD
¿Cuál es el último ingresos anual de Arcus Biosciences?
El último ingresos anual de Arcus Biosciences es USD 117M
¿Cuál es el último beneficio anual de Arcus Biosciences?
El último beneficio anual de Arcus Biosciences es USD -307M
¿Cuál es la dirección registrada de Arcus Biosciences?
La dirección registrada de Arcus Biosciences es 2140 S DUPONT HWY, KENT, CAMDEN, DELAWARE, 19934
¿Cuál es la dirección del sitio web de Arcus Biosciences?
La dirección del sitio web de Arcus Biosciences es www.arcusbio.com
¿En qué sector industrial opera Arcus Biosciences?
Arcus Biosciences opera en el sector PHARMACEUTICAL PREPARATIONS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
ARLAmerican Realty Investors Inc
US$ 15.93
(15.02%)
10.76k
RBOTVicarious Surgical Inc
US$ 16.382
(14.88%)
52.57k
AUNAAuna SA
US$ 8.45
(14.81%)
233.16k
MYTEMYT Netherlands Parent BV
US$ 9.45
(12.23%)
354.61k
BKSYBlackSky Technology Inc
US$ 11.71
(12.06%)
1.7M
SESSES AI Corporation
US$ 0.9369
(-9.91%)
51.58M
DMDesktop Metal Inc
US$ 2.19
(-9.88%)
547.32k
JKSJinkosolar Holdings Co Ltd
US$ 21.23
(-9.81%)
1.55M
BODIBeachbody Company Inc
US$ 6.60
(-9.59%)
19.82k
QBTSD Wave Quantum Inc
US$ 5.275
(-9.21%)
76.53M
QBTSD Wave Quantum Inc
US$ 5.275
(-9.21%)
76.53M
FFord Motor Company
US$ 10.18
(1.70%)
60.8M
BBDBanco Bradesco SA
US$ 1.96
(-1.01%)
59.92M
VALEVale SA
US$ 8.94
(1.94%)
59.4M
SESSES AI Corporation
US$ 0.9369
(-9.91%)
51.58M

RCUS Discussion

Ver más
Monksdream Monksdream 4 meses hace
RCUS a buy under $14
👍️0
PennyWorld PennyWorld 1 año hace
https://seekingalpha.com/news/4005456-roche-send-anti-tigit-developers-higher-after-cancer-drug-data?ref=biztoc.com
👍️0
conix conix 3 años hace
Biotechs are starting to react to news...finally.
👍️0
dinogreeves dinogreeves 5 años hace
The stock didn't react as well as expected with the partnership, but it did hi almost my price target. This is a partnership 200 million equity investment and 175 million up front payment, which. implies no offering on the table. Makes you wonder why the stock is down, guess people were expecting a buyout. Some of these people are so lame, unbelievable.
👍️0
lovetc lovetc 5 años hace
Also in the DEF 14.....didnt see any information regarding Gilead....
👍️0
lovetc lovetc 5 años hace
shorted some and bought some put at $31 last Friday....Also today when it reached $30 I short.....I find no reason not to short above $30 lol....It will be $18 soon since the Volumn start declined....
👍️0
dinogreeves dinogreeves 5 años hace
RCUS will likely hit 40 this week and if it does that could essentially mean that there is buyout looming from GI*LD. Someone is buying heavy between 27-29 dollars, obviously they don't want it dip more than 26-27 dollars, it could be a number of reasons that is beyond any retails control.
👍️0
dinogreeves dinogreeves 5 años hace
Bought another 1000 shares on that dip, going to wait this one.
👍️0
dinogreeves dinogreeves 5 años hace
Possible huge asset buy, or outright buyout coming from GILD or even a partnership.
👍️0
dinogreeves dinogreeves 5 años hace
RCUS getting ready to pop to 33-35 dollars.
👍️0
dinogreeves dinogreeves 5 años hace
This is my letter to the shorts with margin account


That is where dummies like you are mistaken. If GILD places anywhere close to that dollar amount this stock jumps over triple digits in less then 2 hours and if there is buyout it won't even let you blink, just one share will it to the buyout price. If GOOGLE has 17% stake on this company and GILD is looking to either buy or take a stake, there must be something that you and I are not aware of the current directors sold their pervious company to Bristol for 1.5 billion dollars. There is more here than meets the eye. I am taking my chance because if no balls no glory and when that happens short margin account will be vaporized.


https://markets.businessinsider.com/news/stocks/arcus-biosciences-stock-spikes-reports-gilead-investing-cancer-drug-biotech-2020-4-1029100118
👍️0
dinogreeves dinogreeves 5 años hace
If this happens the stock will shoot up to over $200 dollars in an instant. Only if that happens.



https://markets.businessinsider.com/news/stocks/arcus-biosciences-stock-spikes-reports-gilead-investing-cancer-drug-biotech-2020-4-1029100118
👍️0
dinogreeves dinogreeves 5 años hace
News could come from GI*LD that there is a buyout. Watch for news.
👍️0